A HEMATOLOGIC CANCER THAT CAN BE DANGEROUSLY UNSEEN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematologic cancer that has remained underdetected, primarily because of overlapping presentations and morphologically minute distinctions between other malignancies. Now, by including a triad of signature markers—CD123, CD4, and CD56—in all initial hematologic diagnostic panels, proper diagnosis is possible.1-3
BPDCN is an aggressive hematologic cancer and may present with features similar to AML, NHL, ALL, MDS, and CMML, as well as other malignancies with skin manifestations.2-5
CD123, as part of the signature marker triad in combination with CD4 and CD56, is a key marker in identifying BPDCN—and is a rapidly emerging target for therapeutic research in several hematologic cancers.3
Stemline Therapeutics, Inc. is committed to advancing therapeutic research to help patients with BPDCN.
CMML = chronic myelomonocytic leukemia.
References:
- Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111.
- Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279-289.
- Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
- Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367.
- León-Martínez G, Meillón-García L, Morales-Polanco M, Soler-Montecinos L, Ortiz-Hidalgo C. Unusual morphologic presentations of blastic plasmacytoid dendritic cell neoplasm: report of two cases misdiagnosed as melanoma and leprosy. Int J Surg Pathol. 2014;22(1):76-82.